Peptide News Digest

Mounjaro Heart Approval in Canada, Larazotide Phase 3 Plan for Celiac Disease, AI Chatbots on BPC-157

Canada approves Mounjaro to lower heart risk, a celiac peptide gets a new Phase 3 plan, and a study grades what AI chatbots say about BPC-157.

10 stories · Covering regulatory, clinical-trials, industry, research

Editor's Note

BPC-157 shows up twice today, and in two very different places. A Case Western team found that AI chatbots mostly describe it accurately but leave things out, while Instagram's Meta AI endorsed it after surgery. Peptide Development Labs, which starts trading in Canada on November 20, says it wants to take an injectable BPC-157 drug through formal regulatory review, the route that compounded peptides skip. Larazotide is a reminder of how long that route can be: a 342-patient Phase 2b trial met its goal, an earlier Phase 3 was stopped in 2022, and a new owner is now trying a gluten-challenge design the FDA recommended. Two records studies call for caution. A Duke-led analysis linked GLP-1 use to a 58% lower hazard of death in the first year with head and neck cancer, an effect size that yesterday's Mayo Clinic endometrial cancer study suggests can depend heavily on how the comparison group is built. On the regulatory side, Health Canada added a heart-protection use for Mounjaro based on a trial in which tirzepatide matched dulaglutide, and the FDA gave NervGen's spinal cord injury peptide a breakthrough designation.

Health Canada Approves Mounjaro to Lower the Risk of Heart Attack, Stroke, and Cardiovascular Death in Type 2 Diabetes

Health Canada added a new use for Lilly's Mounjaro (tirzepatide): lowering the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease, Lilly Canada announced November 18. The approval rests on SURPASS-CVOT, which compared tirzepatide with dulaglutide (Trulicity) in more than 13,000 people across 30 countries for over four and a half years. Tirzepatide met the trial's non-inferiority goal with an 8% lower rate of these events (hazard ratio 0.92, 95.3% CI 0.83 to 1.01), a range that does not rule out no difference. The release says nothing about price or public coverage.

FDA Grants Breakthrough Therapy Designation to NervGen's NVG-291, a Peptide for Chronic Spinal Cord Injury

NervGen said on November 12 that the FDA gave Breakthrough Therapy designation to NVG-291 for chronic motor-incomplete spinal cord injury in the neck. The daily injected peptide is designed to block a signal from scar tissue (the CSPG-PTPσ pathway) that stops damaged nerve fibers from regrowing. The company says its Phase 1b/2a CONNECT SCI study showed "substantial improvements" in hand function versus placebo, but the release gives no figures. Its Phase 3 RESTORE trial is enrolling about 150 adults in the U.S. and Canada who were injured 1 to 10 years ago, assigned to 12 weeks of NVG-291 or placebo, with grasping ability as the main measure. The designation can speed FDA review but is not an approval.

Interlude Biopharma Plans a 414-Person Phase 3 Trial Testing Whether the Oral Peptide Larazotide Can Prevent Gluten Damage in Celiac Disease

Miami-based Interlude Biopharma said November 19 that it will start a U.S. Phase 3 trial of larazotide acetate, an oral peptide that blocks zonulin to keep the seals between gut-lining cells closed, in the first quarter of 2027. About 414 people aged 12 to 80 with biopsy-confirmed, well-controlled celiac disease will take 0.25 mg or 0.5 mg three times daily, or placebo, for 14 weeks while eating study bars with 500 mg of gluten, first every other day and then daily. The main goal is the share of patients whose intestinal lining and symptoms stay stable. A 342-patient Phase 2b trial met its symptom goal at the 0.5 mg dose, but an earlier Phase 3 trial run by 9 Meters Biopharma was stopped in 2022 after an interim analysis showed it would need too many more patients.

Peptide Development Labs, Which Is Developing an Injectable BPC-157 Drug Candidate, Raises $3 Million Ahead of Its Canadian Listing

Peptide Development Labs, spun out of HYTN Innovations, closed a private placement of 6 million units at 50 cents each for about $3 million and expects its shares to start trading on the Canadian Securities Exchange under the symbol PEPT on November 20. The company says its lead program is an investigational injectable BPC-157 drug candidate for refractory ligament disorders, which it plans to advance through established regulatory pathways. The release names no trial, regulatory filing, or timeline.

Case Western Study: AI Chatbots Gave Mostly Accurate but Incomplete Answers About BPC-157, and Instagram's Meta AI Endorsed It After Surgery

In May 2026, researchers asked seven AI tools and four assistants built into social media apps four standard questions about unapproved peptides such as BPC-157 for musculoskeletal recovery, and two orthopedic surgeons and an immunopathologist graded the dedicated tools' answers. The dedicated tools averaged 21.6 of 30 points on a validated quality scale, from 17.8 for Undermind to 25.3 for Claude, and scored higher for accuracy than for completeness. Instagram's Meta AI claimed BPC-157 speeds recovery and endorsed using it after surgery, and all 11 tools wrote at a college reading level, the authors report in HSS Journal. They conclude that AI tools cannot replace counseling from a clinician.

Duke-Led Records Study Ties GLP-1 Use to Longer Survival in Head and Neck Cancer

In TriNetX records of 4,532 adults with head and neck squamous cell carcinoma, researchers from Duke and Thomas Jefferson University report that GLP-1 drug users had a lower adjusted risk of death than controls at one year (hazard ratio 0.42), three years (0.48), and five years (0.51), with similar results for cancers of the mouth, oropharynx, and larynx. Patients taking both a GLP-1 drug and metformin had a hazard ratio of 0.39 at five years. The study in JAMA Otolaryngology was retrospective, its abstract does not describe how the control group was chosen, and the authors call for prospective studies.

Chi Mei Records Study of 135,216 Adults: Tirzepatide Starters Had Slightly Less Nutritional Anemia Than GLP-1 Starters

Researchers at Chi Mei Medical Center in Taiwan matched 67,608 adults with type 2 diabetes and overweight or obesity who started tirzepatide with the same number who started a GLP-1 drug, using TriNetX records from 2022 to 2026. Within a year, 2.13% of tirzepatide users and 2.84% of GLP-1 users were diagnosed with iron, vitamin B12, or folate deficiency anemia (hazard ratio 0.88, 95% CI 0.83 to 0.95), driven mostly by less iron deficiency anemia. Results for B12 and folate were inconclusive, and the authors write in Diabetes Research and Clinical Practice that leftover confounding limits any causal reading.

Study of 14 GLP-1 Patients at an English GP Practice Finds Many Ate Far Below Their Energy and Nutrient Needs

Fourteen patients prescribed GLP-1 or GIP/GLP-1 drugs at one general practice in England (10 privately and 4 through the NHS) recorded two days of eating. Average intake was 1,231 calories a day, 58.5% of estimated needs, and three people ate under 800 calories. More than three-quarters fell below two-thirds of the reference intake for fiber and vitamin D and about half for iron, while protein averaged 153% of the reference, according to a BMJ summary of the paper in BMJ Nutrition, Prevention & Health. The authors call the small study hypothesis-generating and say no drug-specific nutrition monitoring framework exists.

Chinese Team's Cyclic Peptide GL265 Beat FAP-2286 in Matched Tumor Lesions on PET Scans in a 16-Person Exploratory Study

Researchers at Guilin Medical University and Southern Medical University modified a cyclic peptide that targets fibroblast activation protein (FAP), found in tissue that supports tumors, to make GL264 and GL265. In mice with human tumor grafts, gallium-68-labeled GL265 gave the highest tumor-to-kidney ratios, and its lutetium-177 version was well retained in tumors at 168 hours. In an exploratory study of 16 people, GL265 showed higher uptake and tumor-to-background ratios than the comparator FAP-2286 in matched lesions, and higher uptake than a standard FDG scan in most lesions, the team reports in Advanced Science.

Moscow Randomized Trial: Semaglutide Plus Diet Cut More Weight Than Diet Alone, and Lean Mass Fell in Proportion

At the Moscow Regional Research and Clinical Institute, adults with type 2 diabetes and obesity were randomized to weekly semaglutide (up to 1 mg) plus an individualized diet or to the diet alone in an open-label trial, with 52 patients analyzed. After four months, weight fell 8.65% versus 4.55%, and the semaglutide group lost more lean mass (adjusted difference 2.86 kg). But in both groups each extra kilogram of weight lost came with about 0.4 kg of lean mass, measured by bioelectrical impedance, so the authors, writing in Almanac of Clinical Medicine, found no sign of disproportionate lean mass loss with semaglutide.